KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Receivables - Other (2017 - 2025)

Emergent BioSolutions (EBS) has 9 years of Receivables - Other data on record, last reported at $18.2 million in Q4 2025.

  • For Q4 2025, Receivables - Other fell 7.14% year-over-year to $18.2 million; the TTM value through Dec 2025 reached $18.2 million, down 7.14%, while the annual FY2025 figure was $18.2 million, 7.14% down from the prior year.
  • Receivables - Other reached $18.2 million in Q4 2025 per EBS's latest filing, down from $19.3 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $82.5 million in Q2 2024 and bottomed at $18.2 million in Q4 2025.
  • Average Receivables - Other over 5 years is $46.5 million, with a median of $51.5 million recorded in 2021.
  • Peak YoY movement for Receivables - Other: surged 91.36% in 2021, then tumbled 72.24% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $51.6 million in 2021, then rose by 10.85% to $57.2 million in 2022, then dropped by 10.14% to $51.4 million in 2023, then tumbled by 61.87% to $19.6 million in 2024, then decreased by 7.14% to $18.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $18.2 million in Q4 2025, $19.3 million in Q3 2025, and $22.9 million in Q2 2025.